J. Wedzicha (London, United Kingdom), G. Brusselle (Ghent, Belgium)
LATE-BREAKING ABSTRACT: Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study
C. Vogelmeier, E. Bateman, J. Pallante, H. Bryant, V. Alagappan, P. D‘Andrea, E. He, D. Banerji (Marburg, Germany; , South Africa; East Hanover, United States Of America; Horsham, United Kingdom)
|  |
Accuracy in assessment of acute asthma needs improved to avoid potential adverse outcomes
S. Tsim, L. Bridges, G. Murphy, P. Kewin (Glasgow, United Kingdom)
|  |
Impact of a single chronic obstructive pulmonary disease (COPD) exacerbation on lung function decline: Analysis of UPLIFT®
D. Halpin, M. Decramer, B. Celli, A. Martín, I. Leimer, N. Metzdorf, D. Tashkin (Exeter, United Kingdom; Leuven, Belgium; Boston, New York, Los Angeles, United States Of America; Ingelheim, Germany)
| |
Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAIN
P.W. Jones, D. Singh, A. Agusti, E.D. Bateman, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (London, Manchester, United Kingdom; Barcelona, Spain; Cape Town, South Africa)
| |
Increased risk of mortality in COPD patients using tiotropium respimat vs. tiotropium Handihaler
K. Verhamme, A. Afonso, S. Romio, B. Stricker, G. Brusselle, M. Sturkenboom (Rotterdam, Netherlands; Ghent, Belgium)
| |
The anti-IL-17A-antibody secukinumab does not attenuate ozone induced acute airway neutrophilia in healthy volunteers
A. Kirsten, H. Watz, F. Pedersen, O. Holz, R. Smith, G. Bruin, S. Koehne-Voss, H. Magnussen, D.A. Waltz (Grosshansdorf, Hanover, Germany; Horsham, United Kingdom; Basel, Switzerland; Cambridge, United States Of America)
| |
Reductions in exacerbations with omalizumab in a real-world setting
G.J. Braunstahl, A. Georgiou, J. Canvin, R. Maykut, J. Bruce, C.W. Chen (Rotterdam, Netherlands; Nycosia, Cyprus; Horsham, United Kingdom; Basel, Switzerland; East Hanover, United States Of America)
| |
Improvement in asthma severity and control by voriconazole and posaconazole in severe asthma with fungal sensitization (SAFS) and ABPA
L. Chishimba, R. Niven, D. Denning (Manchester, United Kingdom)
| |